Public Profile

DUSA Pharmaceuticals Inc.

DUSA Pharmaceuticals Inc., a prominent player in the dermatology sector, is headquartered in the United States. Founded in 1991, the company has established itself as a leader in developing innovative therapies for skin conditions, particularly in the treatment of actinic keratosis and acne. DUSA's flagship product, Levulan® Kerastick®, is renowned for its unique photodynamic therapy approach, setting it apart in the competitive dermatological landscape. With a strong focus on research and development, DUSA Pharmaceuticals has achieved significant milestones, including expanding its product portfolio and enhancing patient access to effective treatments. The company’s commitment to quality and innovation has solidified its market position, making it a trusted name among healthcare professionals and patients alike.

DitchCarbon Score

How does DUSA Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

27

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

DUSA Pharmaceuticals Inc.'s score of 27 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.

46%

Let us know if this data was useful to you

DUSA Pharmaceuticals Inc.'s reported carbon emissions

DUSA Pharmaceuticals Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their carbon footprint or climate commitments. However, the absence of documented reduction initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. As the pharmaceutical industry increasingly prioritises sustainability, DUSA Pharmaceuticals may need to establish clear climate goals and reporting practices to align with industry standards and stakeholder expectations.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. DUSA Pharmaceuticals Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for DUSA Pharmaceuticals Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

DUSA Pharmaceuticals Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

FRONTERA

US
Pharmaceutical Preparation Manufacturing
Updated 11 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers